PD05-03 ANDROGEN DEPRIVATION THERAPY (ADT) FOR PROSTATE CANCER AND ITS EFFECTS ON BRAIN VOLUME 3D PLANIMETRY

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) I (PD05)1 Sep 2021PD05-03 ANDROGEN DEPRIVATION THERAPY (ADT) FOR PROSTATE CANCER AND ITS EFFECTS ON BRAIN VOLUME 3D PLANIMETRY Ruel Neupane, Megan Prunty, Danly Omil-Lima, Amr Mahran, Kirtishri Mishra, Lee Ponsky, Carvell Nguyen, Christopher Kondray, Adam Calaway, and Laura Bukavina Ruel NeupaneRuel Neupane More articles by this author , Megan PruntyMegan Prunty More articles by this author , Danly Omil-LimaDanly Omil-Lima More articles by this author , Amr MahranAmr Mahran More articles by this author , Kirtishri MishraKirtishri Mishra More articles by this author , Lee PonskyLee Ponsky More articles by this author , Carvell NguyenCarvell Nguyen More articles by this author , Christopher KondrayChristopher Kondray More articles by this author , Adam CalawayAdam Calaway More articles by this author , and Laura BukavinaLaura Bukavina More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001969.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Approximately 1 in 9 American men will be diagnosed with prostate cancer. Androgen Deprivation Therapy (ADT) is commonly given for advanced local and metastatic prostate cancer with evidence of prolonged survival. However, there is increasing concern for the negative side effects including cognitive decline in ADT users. Our study seeks to quantify radiographic changes on brain parenchyma following ADT. METHODS: A retrospective multi-institutional study was performed on baseline and follow-up computerized tomography (CT) head scans of 59 men prior to and after initiation of ADT. All CT imaging were reviewed using 3D planimetry software (3D Splicer, Version 4.10.2). Brain and ventricular volumes were assessed via segmentation protocol. Multivariate logistic regression (MVR) adjusting for socio-demographic variables and comorbidities were used to assess risk factors for cortical loss. Paired Wilcoxon test was utilized to assess change in brain volume prior to and after initiation of ADT. RESULTS: A total of 59 patients were analyzed. An average decline in cortical volume of 86.2 cm3 [pre-ADT 1156.0 cm3 (1035.0, 1231.5) and post-ADT 1073.0cm3 (930.5, 1136.5), p>0.001] was seen in our cohort. As expected, sequential increase of 30% in ventricular volume from baseline (66 cm3) to post-ADT (84 cm3) was also noted. On MVR, lower BMI (OR 1.13, 95%CI 1,01-1.27, p=0.042), history of dementia (OR 3.47, 95% CI 1.05-12.66, p=0.042) and alcohol abuse (OR 4.7, 95%, CI 1.1-21.01, p=0.037) were all significantly associated with increased the risk of cortical loss. History of metastatic prostate cancer was not associated with risk of cortical loss (Figure 1C). CONCLUSIONS: Androgen deprivation therapy is commonly used for the management of localized and metastatic prostate cancer. There is mounting evidence that ADT may be correlated with loss of brain volume and cognitive decline. In this study we quantify the loss of cortical brain volume and ventricular expansion in patients on ADT. Source of Funding: N/A © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e56-e56 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ruel Neupane More articles by this author Megan Prunty More articles by this author Danly Omil-Lima More articles by this author Amr Mahran More articles by this author Kirtishri Mishra More articles by this author Lee Ponsky More articles by this author Carvell Nguyen More articles by this author Christopher Kondray More articles by this author Adam Calaway More articles by this author Laura Bukavina More articles by this author Expand All Advertisement Loading ...